Download PDF
Semin Thromb Hemost 2020; 46(08): 977-985
DOI: 10.1055/s-0040-1718891
Review Article

Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial

Clive Kearon
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Marc Carrier
2   Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, Ontario, Canada
,
Chu-Shu Gu
3   Department of Oncology, McMaster University, Hamilton, Ontario, Canada
,
Sam Schulman
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
4   Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
,
Shannon M. Bates
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Susan R. Kahn
5   Department of Medicine, McGill University, Montreal, Quebec, Canada
,
Isabelle Chagnon
6   Department of Medicine, University of Montreal, Montreal, Quebec, Canada
,
Doan Trang Nguyen
6   Department of Medicine, University of Montreal, Montreal, Quebec, Canada
,
Cynthia Wu
7   Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
,
Lisa Rudd-Scott
3   Department of Oncology, McMaster University, Hamilton, Ontario, Canada
,
Jim A. Julian
3   Department of Oncology, McMaster University, Hamilton, Ontario, Canada
› Author Affiliations Funding The study was funded by an investigator-initiated grant from Bayer Inc.
› Further Information
    Permissions and Reprints

Abstract

The role of rivaroxaban in the treatment of leg superficial venous thrombosis (SVT) is uncertain. This article aims to determine if rivaroxaban is an effective and safe treatment for leg SVT. Patients with symptomatic leg SVT of at least 5 cm length were randomized to 45 days of rivaroxaban 10 mg daily or to placebo, and followed for a total of 90 days. Treatment failure (required a nonstudy anticoagulant; had proximal deep vein thrombosis or pulmonary embolism; or had surgery for SVT) at 90 days was the primary efficacy outcome. Secondary efficacy outcomes included leg pain severity, and venous disease-specific and general health-related quality of life over 90 days. Major bleeding at 90 days was the primary safety outcome. Poor enrollment led to the trial being stopped after 85 of the planned 600 patients were randomized to rivaroxaban (n = 43) or placebo (n = 42). One rivaroxaban and five placebo patients had a treatment failure by 90 days (absolute risk reduction = 9.0%, 95% confidence interval: −22 to 5.9%). Leg pain improvement did not differ at 7 (p = 0.16) or 45 days (p = 0.89), but was greater with rivaroxaban at 90 days (p = 0.011). There was no difference in venous disease-specific (p = 0.99) or general health-related (p = 0.37) quality of life over 45 days. There were no major bleeds or deaths in either group. There were no identifiable differences in efficacy or safety between rivaroxaban and placebo in patients with symptomatic SVT but comparisons were undermined by a much smaller than planned sample size (NCT1499953).

Keywords

superficial vein - clinical trial - treatment - leg - venous thrombosis

Trial Investigators Additional to the Authors

Clinical centers (patients enrolled), collaborators: The Ottawa Hospital—General Campus, Ottawa, Ontario (ON), Canada (25 patients): W. Aikens, L. Castellucci, C. Code, L. Duffett, A. Dugal, M. Forgie, C. Gonsalves, A. Haspect, A. Karovitch, G. Le Gal, S. Reddie, M. Rodger, D. Scarvelis, P. Wells, A. Clement, H. Carr, and A. Pecarski; Hamilton Health Sciences—General Hospital, Hamilton, ON, Canada (16 patients): N. Bedek, J. Douketis, M. Zondag, and J. Eikelboom; Hamilton Health Sciences—Juravinski Hospital, Hamilton, ON, Canada (14 patients): K. de Witt, S. Dodds, P. Gross, A. Iorio, L-A. Linkins, P. Stevens, C. Webb, and J. Weitz; The Jewish General Hospital, Montreal, Quebec (QC), Canada (8 patients): M. Blostein, C. Strulovitch, and V. Tagalakis; Hôpital du Sacré-Cœur, Montreal, QC, Canada (8 patients): M. Goulet, N. Routhier, and G. Marcotte; Hôpital Maisonneuve—Rosemount, Montreal, QC, Canada (6 patients): E. Foldes, J. Kassis, M. Sergerie, M. Quach, J. Trinh Lu, and D. Sylvestre; Hamilton Health Sciences—McMaster University Medical Centre, Hamilton, ON, Canada (5 patients): S. Bates and M. Pai; University of Alberta Hospital, Edmonton, Alberta, Canada (3 patients): L. Bolster, J. Brandwein, L. Larratt, J. Patterson, A. Peters, B. Ritchie, L. Saini, I. Sandhu, M. Tapara, N. Zhu, C. Crittenden, P. Bellot, A. Shirokova, A. Strilchuk, R. Cairns, and S. Cleary.


Independent Adjudication Committee: Drs. S. Schulman, J. Weitz. and L-A. Linkins.


Data Management and Study Coordination: L. Rudd-Scott, E. McGean, and D. McCarty (Ontario Clinical Oncology Group, McMaster University, Hamilton, ON, Canada).


Data Safety Monitoring Committee: Drs. J. Singer, F. Rickles, J. Sussman, and P. Ellis.




Publication History

Article published online:
23 December 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Decousus H, Quéré I, Presles E. POST (Prospective Observational Superficial Thrombophlebitis) Study Group. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med 2010; 152 (04) 218-224
    CrossrefPubMedSearch in Google Scholar
  • 2 Wichers IM, Di Nisio M, Büller HR, Middeldorp S. Treatment of superficial vein thrombosis to prevent deep vein thrombosis and pulmonary embolism: a systematic review. Haematologica 2005; 90 (05) 672-677
    PubMedSearch in Google Scholar
  • 3 Decousus H, Prandoni P, Mismetti P. CALISTO Study Group. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 2010; 363 (13) 1222-1232
    CrossrefPubMedSearch in Google Scholar
  • 4 Cosmi B, Filippini M, Tonti D. STEFLUX Investigators. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). J Thromb Haemost 2012; 10 (06) 1026-1035
    CrossrefPubMedSearch in Google Scholar
  • 5 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (02) e419S-e496S
    CrossrefPubMedSearch in Google Scholar
  • 6 Duffett L, Kearon C, Rodger M, Carrier M. Treatment of superficial vein thrombosis: a systematic review and meta-analysis. Thromb Haemost 2019; 119 (03) 479-489
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Goldman L, Ginsberg J. Superficial phlebitis and phase 3.5 trials. N Engl J Med 2010; 363 (13) 1278-1280
    CrossrefPubMedSearch in Google Scholar
  • 8 Blondon M, Righini M, Bounameaux H, Veenstra DL. Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis. Chest 2012; 141 (02) 321-329
    CrossrefPubMedSearch in Google Scholar
  • 9 Sobieraj DM, Coleman CI, Tongbram V. et al. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis. Pharmacotherapy 2012; 32 (09) 799-808
    CrossrefPubMedSearch in Google Scholar
  • 10 Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ 2012; 344: e3675
    CrossrefPubMedSearch in Google Scholar
  • 11 Beyer-Westendorf J, Schellong SM, Gerlach H. SURPRISE investigators. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol 2017; 4 (03) e105-e113
    CrossrefPubMedSearch in Google Scholar
  • 12 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedSearch in Google Scholar